Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 3/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | PTGES | O14684 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20190687 | 0.86 | CYP1A2 (0.47) | SCN5ACYP1A2TRPV3L3MBTL1SCN9A | |
| SCHEMBL20190393 | 0.82 | SCN5A (0.54) | SCN5ATRPV3DGAT1NTRK1 | |
| SCHEMBL23572409 | 0.81 | SCN5A (0.55) | SCN5ACYP1A2TRPV3L3MBTL1SCN9A | |
| SCHEMBL20191045 | 0.78 | SCN5A (0.60) | SCN5ACYP1A2L3MBTL1SCN9ANPSR1 | |
| SCHEMBL20208585 | 0.77 | SCN5A (0.69) | SCN5ANPSR1SMN1; SMN2POLBMAPK1 | |
| SCHEMBL20208586 | 0.77 | SCN5A (1.00) | SCN5ACYP1A2L3MBTL1SMN1; SMN2POLB | |
| SCHEMBL20190410 | 0.74 | SCN5A (0.65) | SCN5AL3MBTL1SMN1; SMN2POLBALDH1A1 | |
| SCHEMBL3517867 | 0.73 | SCN5A (0.41) | SCN5ASMN1; SMN2POLBMAPT | |
| SCHEMBL20189530 | 0.71 | SCN5A (0.67) | SCN5AL3MBTL1SMN1; SMN2POLBALDH1A1 | |
| SCHEMBL1332287 | 0.71 | CYP1A2 (0.49) | CYP1A2TRPV3L3MBTL1SCN9ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210188839-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2021-06-24 | — | — | US | disclosed |
| WO-2018098500-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188839-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | SCN5A 8/4885CYP1A2 1988/4885TRPV3 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.